<DOC>
	<DOCNO>NCT01374802</DOCNO>
	<brief_summary>The objective current study investigate effect multiple oral daily dos BI 201335 steady-state pharmacokinetics darunavir co-administered ritonavir .</brief_summary>
	<brief_title>Effect Multiple Dosing With BI 201335 Pharmacokinetics Darunavir Co-administered With Ritonavir Healthy Male Female Volunteers</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>Inclusion criterion : 1 . Healthy male female subject accord follow criterion : medical history , physical examination , vital sign ( blood pressure , pulse rate ) , 12lead electrocardiogram ( ECG ) , clinical laboratory test 2 . Age 18 55 year ( incl . ) 3 . Body Mass Index ( BMI ) 18.5 29.9 kg/m2 ( incl . ) weight great 50 kg 4 . Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation . Exclusion criterion : 1 . Any finding medical examination ( include blood pressure ( BP ) , pulse rate ( PR ) ECG ) deviate normal clinical relevance 2 . Any evidence clinically relevant concomitant disease 3 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 4 . History photosensitivity recurrent rash . 5 . Surgery gastrointestinal tract ( except appendectomy ) 6 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder 7 . History relevant orthostatic hypotension , faint spell blackout . 8 . Chronic relevant acute infection 9 . History relevant allergy/hypersensitivity ( include allergy drug excipients ) 10 . Intake drug long halflife ( 24 hour ) within least one month le 10 halflives respective drug prior administration trial 11 . Participation another trial investigational drug within two month prior administration trial 12 . Smoker ( 10 cigarette ) 13 . Inability refrain smoke trial day 14 . Alcohol abuse ( 30 g/day ) 15 . Drug abuse 16 . Blood donation ( 100 mL within four week prior administration trial ) 17 . ALT outside normal range laboratory value outside reference range clinical relevance 18 . Inability comply dietary regimen trial site 19 . The subject able understand comply protocol requirement , instruction protocolstated restriction 20 . Positive serology test Human immunodeficiency virus ( HIV ) hepatitis B / C virus 21 . Vulnerable subject ( e.g . person keep detention )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>